New developments in topical antifungal therapy

American Journal of Drug Delivery

Volumn 4, Issue 4, 2006, Pages 231-247

  Robert, Majdeline El Mahrab ^a,b   Kalia, Yogeshvar N ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Ctr Interuniv Rech d'Enseignement   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLYLAMINE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BICARBONATE; BUTENAFINE; CAPSOFUNGIN; CARBOMER; CICLOPIROX; CICLOPIROXOLAMINE; CRYSTAL VIOLET; ECHINOCANDIN; ECONAZOLE; EXTINA; FENTICONAZOLE; IMIDAZOLE; INTRALIPID; ITRACONAZOLE; KERATOLYTIC AGENT; KETOCONAZOLE; MICONAZOLE; NATAMYCIN; NYSTATIN; OMOCONAZOLE; OXICONAZOLE; PERMANGANATE POTASSIUM; POLYENE; PYRROLE; PYRROLE DERIVATIVE; SELENIUM SULFIDE; TERBINAFINE; TRIACETIN; TRIAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WHITFIELD OINTMENT;

CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; DERMATOPHYTE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; EYE INFECTION; HUMAN; LIPID COMPOSITION; LIVER TOXICITY; MALASSEZIA; MEMBRANE PERMEABILITY; MOUTH INFECTION; MOUTH MUCOSA; NAIL INFECTION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SKIN INFECTION; STRATUM CORNEUM; VAGINA MUCOSA; VAGINITIS;

EID: 33847188879     PISSN: 11759038     EISSN: None     Source Type: Journal    
DOI: 10.2165/00137696-200604040-00006     Document Type: Review

References (80)

1. Webster GF. Topical medications: a focus on antifungals and topical steroids. Clin Cornerstone 2001; 4 (1): 33-8
2. Schwartz RA. Superficial fungal infections. Lancet 2004; 364 (9440): 1173-82
3. Goldblum D, Frueh BE, Sarra GM, et al. Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model. Antimicrob Agents Chemother 2005; 49 (4): 1359-63
4. Gupta AK, Ryder JE, Chow M, et al. Dermatophytosis: the management of fungal infections. Skinmed 2005; 4 (5): 305-10
5. Borgers M, Degreef H, Cauwenbergh G. Fungal infections of the skin: infection process and antimycotic therapy. Curr Drug Targets 2005; 6 (8): 849-62
6. Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol 1997; 36 (2 Pt 1): S3-8
7. Delevoux M. Candidoses et levuroses divers [Candidiasis and yeast infections]. EMC-Mal Infect 2005; 2: 119-39
8. Gupta AK, Ryder JE, Nicol K, et al. Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis. Clin Dermatol 2003; 21 (5): 417-25
9. Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol 2004; 51 (5): 785-98
10. Kalavathy CM, Parmar P, Kaliamurthy J, et al. Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis. Cornea 2005; 24 (4): 449-52
11. Contet-Audonneau N, Schmutz JL. Antifongiques et mycoses superficielles. Rev Fr Lab 2001; 332: 37-48
12. Aidoo A, Gao N, Neft RE, et al. Evaluation of the genotoxicity of gentian violet in bacterial and mammalian cell systems. Teratog Carcinog Mutagen 1990; 10 (6): 449-62
13. Docampo R, Moreno SN. The metabolism and mode of action of gentian violet. Drug Metab Rev 1990; 22 (2-3): 161-78
14. Shah M. Castellani's paint. Indian J Dermatol Venereol Leprol 2003; 69: 357-8
15. Diehl KB. Topical antifungal agents: an update. Am Fam Physician 1996; 54 (5): 1687-92
16. Hector RF. An overview of antifungal drugs and their use for treatment of deep and superficial mycoses in animals. Clin Tech Small Anim Pract 2005; 20 (4): 240-9
17. Mallié M. Les nouveaux antifongiques et leur stratégies de recherche. Rev Fr Lab 2001; 332: 63-70
18. Georgopapadakou NH. Antifungals: mechanism of action and resistance, established and novel drugs. Curr Opin Microbiol 1998; 1 (5): 547-57
19. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003; 11 (6): 272-9
20. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33 (5): 641-7
21. Canuto D. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002; 2: 550-63
22. Hashiguchi T, Kodama A, Ryu A, et al. Retention capacity of topical imidazole antifungal agents in the skin. Int J Pharm 1998; 161: 195-204
23. Odds F. Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response? Drug Resist Updat 1998; 1: 11-5
24. Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Am Acad Dermatol 1999; 41 (2 Pt 1): 237-49
25. Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs 2006; 15 (6): 579-602
26. Lacroix C, Dubach M, Feuilhade M. Les échinocandines: une nouvelle classe d'antifongiques. Med Mal Infect 2003; 33: 183-91
27. Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin Ther 2005; 27 (6): 657-73
28. Matsumoto Y, Dogru M, Goto E, et al. Successful topical application of a new antifungal agent, micafungin, in the treatment of refractory fungal corneal ulcers: report of three cases and literature review. Cornea 2005; 24 (6): 748-53
29. Ruiz-Herrera J, San-Blas G. Chitin synthesis as target for antifungal drugs. Curr Drug Targets Infect Disord 2003; 3 (1): 77-91
30. De Backer MD, Van Dijck P. Progress in functional genomics approaches to antifungal drug target discovery. Trends Microbiol 2003; 11 (10): 470-8
31. Andrès E, Tiphine M, Letscher-Bru V, et al. Nouvelles formes lipidiques de l'amphotéricine B. Revue de la littérature: review of new lipid formulations of amphotericin B. Rev Med Interne 2001; 22 (2): 141-50
32. Hann IA, Prentice GH. Lipid-based amphotericin B: a review of the last 10 years of use. Int J Antimicrob Agents 2001; 17 (1): 161-9
33. Gabard B, Elsner P, Surber C, Treffel P. Dermatopharmacology of topical preparations: a product-development oriented approach. Berlin: Springer-Verlag, 2000
34. Takahashi H. Some problems in topical antifungals. Biomed Ther 1988; 20: 435-9
35. Uchida K, Yamaguchi H. Studies on the affinity of terbinafine with keratin. Jpn J Med Mycol 1993; 34: 207-12
36. Schaefer H, Stuttgen G. Absolute concentrations of an antimycotic agent, econazole, in the human skin after local application. Arzneimittelforschung 1976; 26 (3): 432-5
37. Craig C, Stitzel RE. Modern pharmacology. 2nd ed. Boston (MA): Little Brown, 1986
38. Ricketti JC. Terbinafine/miconazole nitrate 2% tincture compound for the treatment of onychomycosis. Foot 2001; 11: 21-3
39. Lecha M, Effendy I, Feuilhade de Chauvin M, et al. Treatment options: development of consensus guidelines. J Eur Acad Dermatol Venereol 2005; 19 Suppl. 1: 25-33
40. Effendy I. Therapeutic strategies in onychomycosis. J Eur Acad Dermatol Venereol 1995; 4 (1): 3-10
41. Kobayashi Y, Komatsu T, Sumi M, et al. In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur J Pharm Sci 2004; 21 (4): 471-7
42. Kesavan C, Joyee AG. 5-fluorouracil altered morphology and inhibited growth of Candida albicans. J Clin Microbiol 2005; 43 (12): 6215-6
43. Hui X, Wester RC, Barbadillo S, et al. Ciclopirox delivery into the human nail plate. J Pharm Sci 2004; 93 (10): 2545-8
44. Marty JP. Amorolfine nail lacquer: a novel formulation. J Eur Acad Dermatol Venereol 1995; 4 (1): 17-21
45. Murdan S. Drug delivery to the nail following topical application. Int J Pharm 2002; 236 (1-2): 1-26
46. Flagothier C, Pierard-Franchimont C, Pierard GE. New insights into the effect of amorolfine nail lacquer. Mycoses 2005; 48 (2): 91-4
47. Van Roey J, Haxaire M, Kamya M, et al. Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr 2004; 35 (2): 144-50
48. Moreira D, Paula CR. Vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92 (3): 266-7
49. Karasulu HY, Hilmioglu S, Metin DY, et al. Efficacy of a new ketoconazole bioadhesive vaginal tablet on Candida albicans. Farmaco 2004; 59 (2): 163-7
50. Piemi MP, Korner D, Benita S, et al. Positively and negatively charged submicron emulsions for enhanced topical delivery of antifungal drugs. J Control Release 1999; 58 (2): 177-87
51. Fujii M, Buyuktimkin S, Buyuktimkin N, et al. Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2- (N,N-dimethyl amino)propionate (DDAIP). Int J Pharm 2002; 234 (1-2): 121-8
52. Nesseem DI. Formulation and evaluation of itraconazole via liquid crystal for topical delivery system. J Pharm Biomed Anal 2001; 26 (3): 387-99
53. Bang J. Zone formation in the agar-cup method for determining resistance to antibiotics. Acta Pathol Microbiol Scand 1956; 39 Suppl. 111: 192-3
54. Ketoconazole foam: connetics: connetics ketoconazole foam. Drugs R D 2003; 4 (5): 323-5
55. Huang X, Tanojo H, Lenn J, et al. A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol 2005; 53 (1 Suppl. 1): S26-38
56. Zhang J, Purdon CH, Smith EW. Solid lipid nanoparticles for topical drug delivery. Am J Drug Deliv 2006; 4 (4): 215-20
57. Souto EB, Wissing SA, Barbosa CM, et al. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004; 278 (1): 71-7
58. Altmeyer P, Hoffmann K. Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized, double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43 Suppl. 1: 9-12
59. Abeck D. Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Int J Dermatol 2004; 43 Suppl. 1: 13-6
60. Lebwohl M, Plott T. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43 Suppl. 1: 17-20
61. Gupta AK, Nicol KA. Ciclopirox 1% shampoo for the treatment of seborrheic dermatitis. Int J Dermatol 2006; 45 (1): 66-9
62. Aly R, Katz HI, Kempers SE, et al. Ciclopirox gel for seborrheic dermatitis of the scalp. Int J Dermatol 2003; 42 Suppl. 1: 19-22
63. Dupuy P, Maurette C, Amoric JC, et al. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol 2001; 144 (5): 1033-7
64. Unholzer A, Varigos G, Nicholls D, et al. Ciclopiroxolamine cream for treating seborrheic dermatitis: a double-blind parallel group comparison. Infection 2002; 30 (6): 373-6
65. van Hoogdalem EJ, van den Hoven WE, Terpstra IJ, et al. Nail penetration of the antifungal agent oxiconazole after repeated topical application in healthy volunteers, and the effect of acetylcysteine. Eur J Pharm Sci 1997; 5: 119-27
66. Kobayashi Y, Miyamoto M, Sugibayashi K, et al. Enhancing effect of N-acetyl-l-cysteine or 2-mercaptoethanol on the in vitro permeation of 5-fluorouracil or tolnaftate through the human nail plate. Chem Pharm Bull (Tokyo) 1998; 46 (11): 1797-802
67. Baran R, Coquard F. Combination of fluconazole and urea in a nail lacquer for treating onychomycosis. J Dermatolog Treat 2005; 16 (1): 52-5
68. Davies KJ. Study to determine the efficacy of clotrimazole 1% cream for the treatment of onychomycosis in association with the mechanical reduction of the nail plate. Foot 2006; 16: 19-22
69. Hui X, Chan TC, Barbadillo S, et al. Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. J Pharm Sci 2003; 92 (1): 142-8
70. Morganti F, Bramanti E, Solaro R. Thermal and spectroscopic characterization of interactions between 2-nonyl-1,3-diozolane and stratum corneum components. J Bioact Compat Polym 2000; 14: 162-77
71. Samour CM, Krauser SF, inventors. Antifungal nail lacquer and method using same. Patent 6,224,887. 2001 May 1
72. Humphrey KM, Cork MJ, Haycox A. A retrospective cost-effectiveness analysis of the treatment of onychomycosis in general practice. Br J Dermatol 1998; 139 (4): 660-4
73. Farhi D, Viguier M, Cosnes A, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology 2006; 212 (1): 59-65
74. Senel S, Ikinci G, Kas S, et al. Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal delivery. Int J Pharm 2000; 193 (2): 197-203
75. Patel MP, Cruchley AT, Coleman DC, et al. A polymeric system for the intra-oral delivery of an anti-fungal agent. Biomaterials 2001; 22 (17): 2319-24
76. Dellenbach P, Thomas JL, Guerin V, et al. Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories. Int J Gynaecol Obstet 2000; 71 Suppl. 1: S47-52
77. Ning M, Gu Z, Pan H, et al. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antifungal drug clotrimazole. Indian J Exp Biol 2005; 43 (2): 150-7
78. Ning M, Guo Y, Pan H, et al. Preparation, in vitro and in vivo evaluation of liposomal/niosomal gel delivery systems for clotrimazole. Drug Dev Ind Pharm 2005; 31 (4-5): 375-83
79. Walters KA, Flynn GL, Marvel JR. Penetration of the human nail plate: the effects of vehicle pH on the permeation of miconazole. J Pharm Pharmacol 1985; 37 (7): 498-9
80. Baden HP, Goldsmith LA, Fleming B. A comparative study of the physicochemical properties of human keratinized tissues. Biochim Biophys Acta 1973; 322 (2): 269-78